Instagram Outage Disrupts Thousands of U.S. Users 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
BRISBANE, Calif., March 08, 2016 -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today announced the receipt of positive coverage from TRICARE® National Insurance for AlloMap®.
As a part of the military health system, TRICARE is the health care program for active and returned service members and their dependents. TRICARE has over 9 million lives covered in their programs. This positive coverage decision applies to all TRICARE regions and offers retroactive coverage of AlloMap from February 2015 onwards.
“The positive coverage decision for AlloMap by TRICARE is deserved by individuals in the military and their beneficiaries who are heart transplant patients,” said Jim Yee, MD PhD, Chief Medical Officer. “Our military service population who are covered by TRICARE will now have the same access that is available through non-military health plans. We hope that this decision will ensure that patients covered by TRICARE will no longer have barriers to access AlloMap testing services.”
About CareDx
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients. The company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate/severe acute cellular rejection. CareDx is also pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure, its next-generation sequencing–based test to detect donor-derived cell-free DNA after transplantation. For more information, please visit: www.CareDx.com
Media Contacts – CareDx Molly Martell, Senior Director, Marketing T: +1 415-728-6307 E: [email protected] Media Contacts - Investor Jamar Ismail, Vice President Westwicke Partners, LLC T: +1 650-996-8777 E: [email protected]
